FDA Rejection Challenges Summit Therapeutics' Valuation After Flagship Cancer Drug Setback

Miami, Sunday, 15 November 2026.
The FDA declined Summit Therapeutics’ lung cancer application because ivonescimab failed to significantly extend patient survival, challenging the company’s $11 billion market valuation despite proven tumor-delay benefits.